According to Dizhe Pharmaceutical's announcement, the first half of 2026 is expected to achieve operating income of about 522 million yuan, an increase of 47.04% year on year; R&D expenses of about 402 million yuan, a year-on-year decrease of 1.54%; net loss attributable to owners of the parent company is about 210 million yuan, a year-on-year reduction of 44.35%; after deducting non-net loss of about 231 million yuan, a year-on-year loss reduction of 44.90%. The increase in performance was due to an increase in the market share of approved products. Furthermore, in July, the company signed an agreement with AstraZeneca to grant it exclusive global development and commercialization rights for Schwarzer®, and the deal is uncertain.

According to Dizhe Pharmaceutical's announcement, the first half of 2026 is expected to achieve operating income of about 522 million yuan, an increase of 47.04% year on year; R&D expenses of about 402 million yuan, a year-on-year decrease of 1.54%; net loss attributable to owners of the parent company is about 210 million yuan, a year-on-year reduction of 44.35%; after deducting non-net loss of about 231 million yuan, a year-on-year loss reduction of 44.90%. The increase in performance was due to an increase in the market share of approved products. Furthermore, in July, the company signed an agreement with AstraZeneca to grant it exclusive global development and commercialization rights for Schwarzer®, and the deal is uncertain.